Protein-based therapeutics have led to new paradigms in disease treatment. Projected to be
half of the top ten selling drugs in 2023, proteins have emerged as rivaling and, in some …

Antibody–drug conjugates (ADCs) are a promising cancer treatment modality that enables
the selective delivery of highly cytotoxic payloads to tumours. However, realizing the full …

Antibody–drug conjugates (ADCs) harness the highly specific targeting capabilities of an
antibody to deliver a cytotoxic payload to specific cell types. They have garnered …

Over 20 years ago, the pyrrolysine encoding translation system was discovered in specific
archaea. Our Review provides an overview of how the once obscure pyrrolysyl-tRNA …

Antibody–drug conjugates (ADCs) are targeted immunoconjugate constructs that integrate
the potency of cytotoxic drugs with the selectivity of monoclonal antibodies, minimizing …

The emerging inverse electron demand Diels–Alder (IEDDA) reaction stands out from other
bioorthogonal reactions by virtue of its unmatchable kinetics, excellent orthogonality and …

Abstract Antibody Drug Conjugate (ADC) is an emerging technology to overcome the
limitations of chemotherapy by selectively targeting the cancer cells. ADC binds with an …

The antibody-drug conjugate (ADC), a humanized or human monoclonal antibody
conjugated with highly cytotoxic small molecules (payloads) through chemical linkers, is a …

Antibody-drug conjugates (ADCs) are a rapidly expanding class of biotherapeutics that
utilize antibodies to selectively deliver cytotoxic drugs to the tumor site. As of May 2021, the …

Nature has produced intricate machinery to covalently diversify the structure of proteins after
their synthesis in the ribosome. In an attempt to mimic nature, chemists have developed a …